Clinical Trials Search | Clareo Health

Showing 1-1 of 1 trials

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

NCT05910827

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Esophageal Squamous Cell Carcinoma+4 more

Hummingbird Bioscience398 participantsStarted Feb 2024

Sydney, New South Wales, Australia • Westmead, New South Wales, Australia • Brisbane, Queensland, Australia +17 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers